Medivation Aims For 2010 Approval Of Alzheimer’s Drug Dimebon
This article was originally published in The Pink Sheet Daily
Executive Summary
The neuroprotectant's novel mechanism of action makes it a good candidate for Alzheimer's disease drug cocktails, CEO Hung says.